AR and prostate carcinoma: Since the discovery, in the 1940s, that prostate cancer is dependent on the male sex hormones [1], initially castration and subsequently various forms of ADT, either alone or combined with androgen receptor (AR) antagonists, have been the main therapy for metastatic disease.